AstraZeneca PLC (BCBA:AZN)
Argentina · Delayed Price · Currency is ARS | Market Cap | 400.27T +63.0% |
| Revenue (ttm) | 85.25T +8.6% |
| Net Income | 14.84T +45.3% |
| EPS | 9,492.16 +45.3% |
| Shares Out | n/a |
| PE Ratio | 26.97 |
| Forward PE | 17.98 |
| Dividend | 1,059.17 (1.57%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 41 |
| Average Volume | 212 |
| Open | 67,800 |
| Previous Close | 67,500 |
| Day's Range | 67,300 - 67,850 |
| 52-Week Range | 36,850 - 79,800 |
| Beta | n/a |
| RSI | 30.55 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
Global drug giants double down on China amid trend to build self-reliant supply chains
AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a group of foreign players building new plants ...
AstraZeneca to build Shanghai mega-plant as it steps up investment in China after snubbing UK
The pharmaceutical giant will build a manufacturing hub and innovation centre as it invests £108bn in China before 2030 to make cell therapies.
Jacobio Pharma Poised To Turn A Profit From Precision Cancer Drugs
The Chinese firm is pocketing an upfront payment for a gene-focused drug under development and anticipates rising sales of an approved treatment for lung cancer image credit: Bamboo Works Key Takeaway...
AstraZeneca says it will build cell therapy base, innovation centre in Shanghai
AstraZeneca said on Thursday it will build a cell therapy manufacturing and supply base and innovation centre in Shanghai, aiming to become the first global drugmaker with end-to-end cell thera...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Ruling
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Ruling
AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer
Imfinzi is approved in the EU to treat early-stage gastric and gastroesophageal cancers in combination with chemotherapy.
Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report
Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report
AZN Stock Experiences Slight Dip in Morning Trading
AZN Stock Experiences Slight Dip in Morning Trading
AstraZeneca (AZN) Refutes Takeover Speculation
AstraZeneca (AZN) Refutes Takeover Speculation
AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax
AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax
AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax
AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax
AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares
AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong cli...
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong c...
Health Rounds: Death from dementia on the rise among people with type 2 diabetes
In people with type 2 diabetes in the world's richest countries, deaths from cardiovascular disease are declining while mortality from dementia is on the rise, a large analysis has found.
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proac...
Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn
UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds Business live – latest updates The pipeline of drugs to fight superbugs remains “worryingly thin” and ...
AstraZeneca Announces Approval Of Koselugo In Canada
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said Alexion, AstraZeneca Rare Disease's Koselugo has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 who...
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment
Daiichi Sankyo: FDA Grants Priority Review For ENHERTU
(RTTNews) - Daiichi Sankyo (4568.T) and AstraZeneca's (AZN, AZN.L, ZEG.DE, AZN.ST) supplemental Biologics License Application for ENHERTU has been accepted and granted Priority Review in the U.S. for ...
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop
Exxon Mobil, Palantir and AstraZeneca lead Zacks' latest analyst reports, highlighting strong production growth, AI momentum and a robust drug pipeline.